APOB and cardiovascular disorder: According to the recent guidelines of the European Society of Cardiology on cardiovascular disease prevention in clinical practice, non-HDL cholesterol, including all atherogenic (Apo-B-containing) lipoproteins, is used as an input in the Systemic Coronary Risk Estimation 2 (SCORE2) and SCORE2-Older Persons (SCORE2-OP) risk algorithms [22].